2010
DOI: 10.1097/cmr.0b013e328334c39a
|View full text |Cite
|
Sign up to set email alerts
|

Primary malignant melanoma at unusual sites: an institutional experience with review of literature

Abstract: Apart from the skin and choroid plexus, primary malignant melanoma is rare at the other sites and lacks organized documentation. Here, we have tried to enumerate the primary malignant melanomas at various atypical sites, supported by literature review. Seventeen cases were identified from our records of the past 5 years, which had detailed clinical work-up to exclude a possibility of a metastasis. A clear female predominance with involvement of the lower genitourinary tract was identified. In addition to three… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
28
0
2

Year Published

2011
2011
2019
2019

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 39 publications
(30 citation statements)
references
References 30 publications
0
28
0
2
Order By: Relevance
“…Specifically, it is unclear if treatment strategies should follow current practice regarding female genital tract cancer or should be extrapolated from established strategies used for cutaneous melanomas (11,12). In addition, the clinical rationale of molecular tumor characterization of PMV regarding BRAF, KIT, or NRAS as well as the therapeutic value of immunotherapies and targeted therapies such as the monoclonal antibodies to the programmed cell death protein-1 (PD-1) nivolumab and pembrolizumab and the antibody to the cytotoxic Tlymphocyte-associated protein 4 (CTLA-4) ipilimumab has not been established for patients with PMV (13).…”
mentioning
confidence: 99%
“…Specifically, it is unclear if treatment strategies should follow current practice regarding female genital tract cancer or should be extrapolated from established strategies used for cutaneous melanomas (11,12). In addition, the clinical rationale of molecular tumor characterization of PMV regarding BRAF, KIT, or NRAS as well as the therapeutic value of immunotherapies and targeted therapies such as the monoclonal antibodies to the programmed cell death protein-1 (PD-1) nivolumab and pembrolizumab and the antibody to the cytotoxic Tlymphocyte-associated protein 4 (CTLA-4) ipilimumab has not been established for patients with PMV (13).…”
mentioning
confidence: 99%
“…Less than 150 cases of primary vaginal melanoma have been reported in the literature to date. In the recent 5 years, only 3 cases have been reported (2).…”
Section: Discussionmentioning
confidence: 99%
“…This melanoma is a highly aggressive tumor with an overall 5-year survival rate of 0-20% (1). Less than 150 cases of primary vaginal melanoma have been identified in a review of literature (2). Furthermore, metastasis of a malignant tumor to the gastrointestinal (GI) tract (especially to the papilla of Vater) is uncommon.…”
Section: Introductionmentioning
confidence: 99%
“…Primary melanoma of the genitourinary tract is rare, accounting for less than 1% of all cases of melanoma [1,2], while primary malignant melanoma of the urethra in females represents only 0.2% of all malignant melanomas [3]. Since the clinical presentation of urethral melanoma is similar to that of urothelial carcinoma, there is frequently a delay in diagnosis [4].…”
Section: Introductionmentioning
confidence: 99%